<H1>Chapter DOI: 10.1007/978-1-60327-829-4_3<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>100</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>99</td></tr><tr><td>BibStructured Count</td><td width="10%">100</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>87</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>4</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>4</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>4</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>4</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_3</td><td>BibArticle</td><td>Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2:389&#8211;96.</td><td><a href=http://dx.doi.org/10.1038/nrc801>10.1038/nrc801</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_3</td><td>BibArticle</td><td>Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332&#8211;53.</td><td><a href=http://dx.doi.org/10.1002/pros.20115>10.1002/pros.20115</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_3</td><td>BibArticle</td><td>Mohler JL, Gregory CW, Ford 3rd OH, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440&#8211;8.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-1146-03>10.1158/1078-0432.CCR-1146-03</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_3</td><td>BibArticle</td><td>Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008;617:223&#8211;34.</td><td><a href=http://dx.doi.org/10.1007/978-0-387-69080-3_21>10.1007/978-0-387-69080-3_21</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_3</td><td>BibArticle</td><td>Davison SL, Bell R. Androgen physiology. Semin Reprod Med 2006;24:71&#8211;7.</td><td><a href=http://dx.doi.org/10.1055/s-2006-939565>10.1055/s-2006-939565</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_3</td><td>BibArticle</td><td>Rainey WE, Carr BR, Sasano H, Suzuki T, Mason JI. Dissecting human adrenal androgen production. Trends Endocrinol Metab 2002;13:234&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S1043-2760(02)00609-4>10.1016/S1043-2760(02)00609-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_3</td><td>BibArticle</td><td>Vermeulen A. Reflections concerning biochemical parameters of androgenicity. Aging Male 2004;7:280&#8211;9.</td><td><a href=http://dx.doi.org/10.1080/13685530400016615>10.1080/13685530400016615</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_3</td><td>BibArticle</td><td>Pardridge WM. Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab 1986;15:259&#8211;78.</td><td><a href=http://dx.doi.org/10.1016/S0300-595X(86)80024-X>10.1016/S0300-595X(86)80024-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_3</td><td>BibArticle</td><td>Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 1994;63:25&#8211;61.</td><td><a href=http://dx.doi.org/10.1146/annurev.bi.63.070194.000325>10.1146/annurev.bi.63.070194.000325</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_3</td><td>BibArticle</td><td>Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992;88:15&#8211;22.</td><td><a href=http://dx.doi.org/10.1016/0303-7207(92)90004-P>10.1016/0303-7207(92)90004-P</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_3</td><td>BibArticle</td><td>Wilson EM, French FS. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem 1976;251:5620&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12_3</td><td>BibArticle</td><td>Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765&#8211;71.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-0130>10.1158/0008-5472.CAN-03-0130</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_3</td><td>BibArticle</td><td>Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006;231:12&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/j.canlet.2004.12.037>10.1016/j.canlet.2004.12.037</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_3</td><td>BibArticle</td><td>Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A 2004;101:4758&#8211;63.</td><td><a href=http://dx.doi.org/10.1073/pnas.0401123101>10.1073/pnas.0401123101</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_3</td><td>BibArticle</td><td>Verrijdt G, Tanner T, Moehren U, Callewaert L, Haelens A, Claessens F. The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response. Biochem Soc Trans 2006;34:1089&#8211;94.</td><td><a href=http://dx.doi.org/10.1042/BST0341089>10.1042/BST0341089</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_3</td><td>BibArticle</td><td>Reid KJ, Hendy SC, Saito J, Sorensen P, Nelson CC. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J Biol Chem 2001;276:2943&#8211;52.</td><td><a href=http://dx.doi.org/10.1074/jbc.M009170200>10.1074/jbc.M009170200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_3</td><td>BibArticle</td><td>Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007;28:778&#8211;808.</td><td><a href=http://dx.doi.org/10.1210/er.2007-0019>10.1210/er.2007-0019</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_3</td><td>BibArticle</td><td>Tsai MJ, O&#8217;Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451&#8211;86.</td><td><a href=http://dx.doi.org/10.1146/annurev.bi.63.070194.002315>10.1146/annurev.bi.63.070194.002315</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_3</td><td>BibArticle</td><td>White R, Parker MG. Molecular mechanisms of steroid hormone action. Endocr Relat Cancer 1998;5:1&#8211;14.</td><td><a href=http://dx.doi.org/10.1677/erc.0.0050001>10.1677/erc.0.0050001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_3</td><td>BibArticle</td><td>Lavery DN, McEwan IJ. The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics. Biochem Soc Trans 2006;34:1054&#8211;7.</td><td><a href=http://dx.doi.org/10.1042/BST0341054>10.1042/BST0341054</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_3</td><td>BibArticle</td><td>Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94:3320&#8211;3.</td><td><a href=http://dx.doi.org/10.1073/pnas.94.7.3320>10.1073/pnas.94.7.3320</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_3</td><td>BibArticle</td><td>Schoenmakers E, Verrijdt G, Peeters B, Verhoeven G, Rombauts W, Claessens F. Differences in DNA binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses. J Biol Chem 2000;275:12290&#8211;7.</td><td><a href=http://dx.doi.org/10.1074/jbc.275.16.12290>10.1074/jbc.275.16.12290</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_3</td><td>BibArticle</td><td>Wang Q, Lu J, Yong EL. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 2001;276:7493&#8211;9.</td><td><a href=http://dx.doi.org/10.1074/jbc.M009916200>10.1074/jbc.M009916200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_3</td><td>BibArticle</td><td>Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res 2007;67:4514&#8211;23.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-1701>10.1158/0008-5472.CAN-06-1701</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_3</td><td>BibArticle</td><td>Jenster G, Trapman J, Brinkmann AO. Nuclear import of the human androgen receptor. Biochem J 1993;293:761&#8211;8.</td><td><a href=http://dx.doi.org/10.1042/bj2930761>10.1042/bj2930761</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Year, ArticleTitle, Author_FamilyName_1, VolumeID</td><td>CrossRef</td></tr><tr><td>CR26_3</td><td>BibArticle</td><td>Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH<Subscript>2</Subscript>-terminal and carboxyl-terminal sequences. J Biol Chem 1994;269:13115&#8211;23.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27_3</td><td>BibArticle</td><td>Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997;387:733&#8211;6.</td><td><a href=http://dx.doi.org/10.1038/42750>10.1038/42750</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_3</td><td>BibArticle</td><td>Chang CY, McDonnell DP. Androgen receptor&#8211;cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005;26:225&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/j.tips.2005.03.002>10.1016/j.tips.2005.03.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_3</td><td>BibArticle</td><td>Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687&#8211;97.</td><td><a href=http://dx.doi.org/10.1093/jnci/93.22.1687>10.1093/jnci/93.22.1687</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_3</td><td>BibArticle</td><td>Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488&#8211;90.</td><td><a href=http://dx.doi.org/10.1056/NEJMp048178>10.1056/NEJMp048178</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_3</td><td>BibArticle</td><td>Mohler JL. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008;22:357&#8211;72.</td><td><a href=http://dx.doi.org/10.1016/j.beem.2008.01.009>10.1016/j.beem.2008.01.009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_3</td><td>BibArticle</td><td>Heemers HV, Tindall DJ. Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Curr Cancer Ther Rev 2005;1:175&#8211;86.</td><td><a href=http://dx.doi.org/10.2174/1573394054021745>10.2174/1573394054021745</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_3</td><td>BibArticle</td><td>Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, et al. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen and anti-androgen-induced androgen receptor function. Am J Pathol 2003;162:233&#8211;41.</td><td><a href=http://dx.doi.org/10.1016/S0002-9440(10)63814-X>10.1016/S0002-9440(10)63814-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_3</td><td>BibArticle</td><td>Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR35_3</td><td>BibArticle</td><td>Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003;22:2466&#8211;77.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1206342>10.1038/sj.onc.1206342</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_3</td><td>BibArticle</td><td>Belandia B, Powell SM, Garc&#237;a-Pedrero JM, Walker MM, Bevan CL, Parker MG. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol 2005;25:1425&#8211;36.</td><td><a href=http://dx.doi.org/10.1128/MCB.25.4.1425-1436.2005>10.1128/MCB.25.4.1425-1436.2005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_3</td><td>BibArticle</td><td>Bawa-Khalfe T, Cheng J, Wang Z, Yeh ET. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem 2007;282:37341&#8211;9.</td><td><a href=http://dx.doi.org/10.1074/jbc.M706978200>10.1074/jbc.M706978200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_3</td><td>BibArticle</td><td>Chen PH, Tsao YP, Wang CC, Chen SL. Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. Nucleic Acids Res 2008;36:51&#8211;66.</td><td><a href=http://dx.doi.org/10.1093/nar/gkm942>10.1093/nar/gkm942</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_3</td><td>BibArticle</td><td>Heemers HV, Regan KM, Dehm SM, Tindall DJ. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res 2007;67:10592&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-1917>10.1158/0008-5472.CAN-07-1917</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_3</td><td>BibArticle</td><td>Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman 3rd WE, Erdem H, et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006;66:10594&#8211;602.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-1023>10.1158/0008-5472.CAN-06-1023</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_3</td><td>BibArticle</td><td>Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007;67:3422&#8211;30.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-2836>10.1158/0008-5472.CAN-06-2836</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_3</td><td>BibArticle</td><td>Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004;204:159&#8211;66.</td><td><a href=http://dx.doi.org/10.1002/path.1609>10.1002/path.1609</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_3</td><td>BibArticle</td><td>Shukla S, MacLennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3K-Akt and NF-&#954;B during prostate cancer progression in autochtonous transgenic mouse model. Prostate 2005;64:224&#8211;39.</td><td><a href=http://dx.doi.org/10.1002/pros.20217>10.1002/pros.20217</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_3</td><td>BibArticle</td><td>Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005;64:160&#8211;7.</td><td><a href=http://dx.doi.org/10.1002/pros.20218>10.1002/pros.20218</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_3</td><td>BibArticle</td><td>Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22:2862&#8211;70.</td><td><a href=http://dx.doi.org/10.1128/MCB.22.8.2862-2870.2002>10.1128/MCB.22.8.2862-2870.2002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_3</td><td>BibArticle</td><td>Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, et al. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 2004;279:33438&#8211;46.</td><td><a href=http://dx.doi.org/10.1074/jbc.M401781200>10.1074/jbc.M401781200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_3</td><td>BibArticle</td><td>Link KA, Balasubramaniam S, Sharma A, Comstock CE, Godoy-Tundidor S, Powers N, et al. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res 2008;68:4551&#8211;8.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-6392>10.1158/0008-5472.CAN-07-6392</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_3</td><td>BibArticle</td><td>Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22:179&#8211;84.</td><td><a href=http://dx.doi.org/10.1080/08977190412331279908>10.1080/08977190412331279908</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_3</td><td>BibArticle</td><td>Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004;279:7119&#8211;30.</td><td><a href=http://dx.doi.org/10.1074/jbc.M307649200>10.1074/jbc.M307649200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_3</td><td>BibArticle</td><td>Bai S, Wilson EM. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol 2008;28:1947&#8211;63.</td><td><a href=http://dx.doi.org/10.1128/MCB.01672-07>10.1128/MCB.01672-07</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_3</td><td>BibArticle</td><td>Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277:38087&#8211;94.</td><td><a href=http://dx.doi.org/10.1074/jbc.M203313200>10.1074/jbc.M203313200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_3</td><td>BibArticle</td><td>Pandey PK, Udayakumar TS, Lin X, Sharma D, Shapiro PS, Fondell JD. Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Mol Cell Biol 2005;25:10695&#8211;710.</td><td><a href=http://dx.doi.org/10.1128/MCB.25.24.10695-10710.2005>10.1128/MCB.25.24.10695-10710.2005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_3</td><td>BibArticle</td><td>Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124:615&#8211;29.</td><td><a href=http://dx.doi.org/10.1016/j.cell.2005.12.032>10.1016/j.cell.2005.12.032</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_3</td><td>BibArticle</td><td>Gong J, Zhu J, Goodman Jr OB, Pestell RG, Schlegel PN, Nanus DM, et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 2006;25:2011&#8211;21.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1209231>10.1038/sj.onc.1209231</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55_3</td><td>BibArticle</td><td>Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638&#8211;40.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR56_3</td><td>BibArticle</td><td>Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, et al. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005;65:708&#8211;12.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-2837>10.1158/0008-5472.CAN-04-2837</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57_3</td><td>BibArticle</td><td>Hara T, Honda K, Shitashige M, Ono M, Matsuyama H, Naito K, et al. Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics 2007;6:479&#8211;91.</td><td><a href=http://dx.doi.org/10.1074/mcp.M600129-MCP200>10.1074/mcp.M600129-MCP200</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, VolumeID, Author_FamilyName_2, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR58_3</td><td>BibArticle</td><td>Heitzer MD, DeFranco DB. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 2006;66:7326&#8211;33.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-05-2379>10.1158/0008-5472.CAN-05-2379</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59_3</td><td>BibArticle</td><td>Taneja SS, Ha S, Swenson NK, Torra IP, Rome S, Walden PD, et al. ART-27, an androgen receptor coactivator regulated in prostate development and cancer. J Biol Chem 2004;279:13944&#8211;52.</td><td><a href=http://dx.doi.org/10.1074/jbc.M306576200>10.1074/jbc.M306576200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60_3</td><td>BibArticle</td><td>Heeb&#248;ll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskj&#248;t L, et al. SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol 2008;23:1069&#8211;76.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR61_3</td><td>BibArticle</td><td>Krajewska M, Turner BC, Shabaik A, Krajewski S, Reed JC. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate 2006;66:801&#8211;10.</td><td><a href=http://dx.doi.org/10.1002/pros.20384>10.1002/pros.20384</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62_3</td><td>BibArticle</td><td>M&#228;ki HE, Saram&#228;ki OR, Shatkina L, Martikainen PM, Tammela TL, van Weerden WM, et al. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. J Pathol 2007;212:395&#8211;401.</td><td><a href=http://dx.doi.org/10.1002/path.2186>10.1002/path.2186</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63_3</td><td>BibArticle</td><td>Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 2007;67:203&#8211;13.</td><td><a href=http://dx.doi.org/10.1002/pros.20521>10.1002/pros.20521</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64_3</td><td>BibArticle</td><td>Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004;101:1345&#8211;56.</td><td><a href=http://dx.doi.org/10.1002/cncr.20518>10.1002/cncr.20518</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65_3</td><td>BibArticle</td><td>Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, Neal DE. Alterations in beta-catenin expression and localization in prostate cancer. Prostate 2008;68:1196&#8211;205.</td><td><a href=http://dx.doi.org/10.1002/pros.20780>10.1002/pros.20780</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66_3</td><td>BibArticle</td><td>Hong H, Kao C, Jeng MH, Eble JN, Koch MO, Gardner TA, et al. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer 2004;101:83&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/cncr.20327>10.1002/cncr.20327</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67_3</td><td>BibArticle</td><td>Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 2007;67:614&#8211;22.</td><td><a href=http://dx.doi.org/10.1002/pros.20557>10.1002/pros.20557</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68_3</td><td>BibArticle</td><td>Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003;22:734&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1206121>10.1038/sj.onc.1206121</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69_3</td><td>BibArticle</td><td>Stepanova L, Yang G, DeMayo F, Wheeler TM, Finegold M, Thompson TC, et al. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene 2000;19:2186&#8211;93.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1203561>10.1038/sj.onc.1203561</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70_3</td><td>BibArticle</td><td>Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR71_3</td><td>BibArticle</td><td>Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, et al. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Res 2007;67:4630&#8211;7.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-4556>10.1158/0008-5472.CAN-06-4556</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72_3</td><td>BibArticle</td><td>Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, et al. Comprehensive expression analysis of<Emphasis Type="SmallCaps">l</Emphasis>-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007;38:161&#8211;70.</td><td><a href=http://dx.doi.org/10.1016/j.humpath.2006.07.003>10.1016/j.humpath.2006.07.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73_3</td><td>BibArticle</td><td>Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. Decreased expression of e6-associated protein in breast and prostate carcinomas. Endocrinology 2005;146:1707&#8211;12.</td><td><a href=http://dx.doi.org/10.1210/en.2004-1198>10.1210/en.2004-1198</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74_3</td><td>BibArticle</td><td>Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66:11341&#8211;7.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-1570>10.1158/0008-5472.CAN-06-1570</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75_3</td><td>BibArticle</td><td>Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, et al. Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 2006;118:1108&#8211;19.</td><td><a href=http://dx.doi.org/10.1002/ijc.21469>10.1002/ijc.21469</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76_3</td><td>BibArticle</td><td>Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999;40:14&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0045(19990615)40:1&lt;14::AID-PROS2&gt;3.0.CO;2-6>10.1002/(SICI)1097-0045(19990615)40:1&lt;14::AID-PROS2&gt;3.0.CO;2-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77_3</td><td>BibArticle</td><td>Rao DS, Hyun TS, Kumar PD, Mizukami IF, Rubin MA, Lucas PC, et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 2002;110:351&#8211;60.</td><td><a href=http://dx.doi.org/10.1172/JCI0215529>10.1172/JCI0215529</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Author_FamilyName_1, ArticleTitle, FirstPage, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR78_3</td><td>BibArticle</td><td>Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006;26:3409&#8211;16.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR79_3</td><td>BibArticle</td><td>Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A 2007;104:19226&#8211;31.</td><td><a href=http://dx.doi.org/10.1073/pnas.0700735104>10.1073/pnas.0700735104</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80_3</td><td>BibArticle</td><td>Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, et al. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol 2004;18:2011&#8211;23.</td><td><a href=http://dx.doi.org/10.1210/me.2004-0065>10.1210/me.2004-0065</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81_3</td><td>BibArticle</td><td>Vijayvargia R, May MS, Fondell JD. A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res 2007;67:4034&#8211;41.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-3039>10.1158/0008-5472.CAN-06-3039</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82_3</td><td>BibArticle</td><td>Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X, et al. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A 2008;105:5236&#8211;41.</td><td><a href=http://dx.doi.org/10.1073/pnas.0712262105>10.1073/pnas.0712262105</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83_3</td><td>BibArticle</td><td>Kaur R, Yuan X, Lu ML, Balk SP. Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate 2008;68(14):1510&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/pros.20787>10.1002/pros.20787</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR84_3</td><td>BibArticle</td><td>Black PC, Mize GJ, Karlin P, Greenberg DL, Hawley SJ, True LD, et al. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007;67:743&#8211;56.</td><td><a href=http://dx.doi.org/10.1002/pros.20503>10.1002/pros.20503</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR85_3</td><td>BibArticle</td><td>Nair SS, Guo Z, Mueller JM, Koochekpour S, Qiu Y, Tekmal RR, et al. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol 2007;21:613&#8211;24.</td><td><a href=http://dx.doi.org/10.1210/me.2006-0269>10.1210/me.2006-0269</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86_3</td><td>BibArticle</td><td>Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep 2004;11:1319&#8211;24.</td><td><a href=http://dx.doi.org/10.3892/or.11.6.1319>10.3892/or.11.6.1319</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR87_3</td><td>BibArticle</td><td>Logan IR, Gaughan L, McCracken SR, Sapountzi V, Leung HY, Robson CN. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol 2006;26:6502&#8211;10.</td><td><a href=http://dx.doi.org/10.1128/MCB.00147-06>10.1128/MCB.00147-06</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88_3</td><td>BibArticle</td><td>Metzger E, Yin N, Wissmann M, Kunowska N, Fischer K, Friedrichs N, et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 2008;10:53&#8211;60.</td><td><a href=http://dx.doi.org/10.1038/ncb1668>10.1038/ncb1668</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89_3</td><td>BibArticle</td><td>Zhu A, Zhang CX, Lieberman HB. Rad9 has a functional role in human prostate carcinogenesis. Cancer Res 2008;68:1267&#8211;74.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-2304>10.1158/0008-5472.CAN-07-2304</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90_3</td><td>BibArticle</td><td>Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, et al. The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol 2008;215:67&#8211;77.</td><td><a href=http://dx.doi.org/10.1002/path.2324>10.1002/path.2324</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91_3</td><td>BibArticle</td><td>Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, et al. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res 2007;67:10087&#8211;96.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-1646>10.1158/0008-5472.CAN-07-1646</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92_3</td><td>BibArticle</td><td>Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007;67:6612&#8211;8.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-0085>10.1158/0008-5472.CAN-07-0085</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93_3</td><td>BibArticle</td><td>Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 2007;13:5692&#8211;702.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-1078>10.1158/1078-0432.CCR-07-1078</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94_3</td><td>BibArticle</td><td>Agoulnik IU, Vaid A, Bingman 3rd WE, Erdeme H, Frolov A, Smith CL, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65:7959&#8211;67.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR95_3</td><td>BibArticle</td><td>Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005;65:7976&#8211;83.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR96_3</td><td>BibArticle</td><td>Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001;85:1928&#8211;36.</td><td><a href=http://dx.doi.org/10.1054/bjoc.2001.2179>10.1054/bjoc.2001.2179</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR97_3</td><td>BibArticle</td><td>Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007;97:378&#8211;83.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6603871>10.1038/sj.bjc.6603871</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98_3</td><td>BibArticle</td><td>Zhang H, Zhang Y, Duan HO, Kirley SD, Lin SX, McDougal WS, et al. TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer 2008;123:810&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/ijc.23638>10.1002/ijc.23638</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99_3</td><td>BibArticle</td><td>Miyajima N, Maruyama S, Bohgaki M, Kano S, Shigemura M, Shinohara N, et al. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res 2008;68:3486&#8211;94.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-07-6059>10.1158/0008-5472.CAN-07-6059</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100_3</td><td>BibArticle</td><td>Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, et al. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006;20:2315&#8211;25.</td><td><a href=http://dx.doi.org/10.1210/me.2006-0048>10.1210/me.2006-0048</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>